资讯

MSD and Daiichi announce first subject dosing in prostate cancer trial
MSD and Daiichi Sankyo have announced first subject dosing in the randomised IDeate-Prostate01 Phase III trial of ifinatamab ...
Medical Dialogues19 小时
Phase 3 trial initiated for Ifinatamab Deruxtecan in Pretreated Metastatic Castration ...
Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial ...